Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 2, 2015, Pages 127-134

  Hicks, J K ^a   Bishop, J R ^b   Sangkuhl, K ^c   Muller, D J ^d   Ji, Y ^e   Leckband, S G ^f   Leeder, J S ^g   Graham, R L ^h,i   Chiulli, D L ^j   LLerena, A ^k   Skaar, T C ^l   Scott, S A ^m   Stingl, J C ⁿ   Klein, T E ^c   Caudle, K E ^o   Gaedigk, A ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CHILDREN S MERCY HOSPITAL   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^k UNIVERSITY OF EXTREMADURA   (Spain)

^l INDIANA UNIVERSITY   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ Fed Inst Drugs and Med Devices   (Germany)

^o ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE; CYP2C19 PROTEIN, HUMAN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INCIDENTAL FINDING; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; BIOTRANSFORMATION; DOSE CALCULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; STANDARDS;

BIOTRANSFORMATION; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2D6; DRUG DOSAGE CALCULATIONS; GENOTYPE; HUMANS; PATIENT SAFETY; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84962294272     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.147     Document Type: Article

References (36)

1. Stingl, J.C., Brockmoller, J., & Viviani, R. Genetic variability of drugmetabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol. Psychiatry 18, 273-287 (2013
2. Crews, K.R., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95, 376-382 (2014
3. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J., & Leeder, J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008
4. Sim, S.C., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006
5. Scott, S.A., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013
6. Funk, K.A., & Bostwick, J.R. A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 47, 1330-1341 (2013
7. Mandrioli, R., Mercolini, L., Saracino, M.A., & Raggi, M.A. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr. Med. Chem. 19, 1846-1863 (2012
8. Tang, S.W., & Helmeste, D. Paroxetine. Expert Opin. Pharmacother. 9, 787-794 (2008
9. Whirl-Carrillo, M., et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012
10. Huezo-Diaz, P., et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J. Psychopharmacol. 26, 398-407 (2012
11. Barak, Y., Swartz, M., & Baruch, Y. Venlafaxine or a second SSRI: switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis. Progr. Neuropsychopharmacol. Biol. Psychiatry 35, 1744-1747 (2011
12. Hampton, L.M., Daubresse, M., Chang, H.Y., Alexander, G.C., & Budnitz, D.S. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry 71, 1006-1014 (2014
13. Altar, C.A., Hornberger, J., Shewade, A., Cruz, V., Garrison, J., & Mrazek, D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 25, 509-533 (2013
14. Brandl, E.J., Kennedy, J.L., & Muller, D.J. Pharmacogenetics of antipsychotics. Can. J. Psychiatry 59, 76-88 (2014
15. Muller, D.J., Kekin, I., Kao, A.C., & Brandl, E.J. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int. Rev. Psychiatry 25, 554-571 (2013
16. Charlier, C., Broly, F., Lhermitte, M., Pinto, E., Ansseau, M., & Plomteux, G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther. Drug Monit. 25, 738-742 (2003
17. Gex-Fabry, M., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit. 30, 474-482 (2008
18. Guzey, C., & Spigset, O. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. J. Clin. Psychopharmacol. 26, 211-212 (2006
19. Lam, Y.W., Gaedigk, A., Ereshefsky, L., Alfaro, C.L., & Simpson, J CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22, 1001-1006 (2002
20. Hiemke, C., et al. AGNP Consensus Guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011
21. Carrillo, J.A., Dahl, M.L., Svensson, J.O., Alm, C., Rodriguez, I., & Bertilsson, L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin. Pharmacol. Ther. 60, 183-190 (1996
22. Sawamura, K., Suzuki, Y., & Someya, T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur. J. Clin. Pharmacol. 60, 553-557 (2004
23. Spigset, O., Granberg, K., Hagg, S., Norstrom, A., & Dahlqvist, R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur. J. Clin. Pharmacol. 52, 129-133 (1997
24. Hodgson, K., et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J. Psychopharmacol. 28, 133-141 (2014
25. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. Impact of the ultrarapid CYP2C1917 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322-327 (2008
26. Chen, B., et al. Estimation of CYP2D6 10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. J. Clin. Pharm. Ther. 38, 504-511 (2013
27. Fudio, S., et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur. J. Pharmacol. 626, 200-204 (2010
28. Noehr-Jensen, L., et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur. J. Clin. Pharmacol. 65, 887-894 (2009
29. Rudberg, I., Hermann, M., Refsum, H., & Molden, E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur. J. Clin. Pharmacol. 64, 1181-1188 (2008
30. Wang, J.H., et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther. 70, 42-47 (2001
31. Grasmader, K., et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol. 60, 329-336 (2004
32. Blake, M.J., et al. Ontogeny of dextromethorphan O-And Ndemethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007
33. Bertelsen, K.M., Venkatakrishnan, K., Von Moltke, L.L., Obach, R.S., & Greenblatt, D.J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31, 289-293 (2003
34. Gvozdic, K., Brandl, E.J., Taylor, D.L., & Muller, D.J. Genetics and personalized medicine in antidepressant treatment. Curr. Pharm. Des. 18, 5853-5978 (2012
35. LLerana, A., Berecz, R., de la Rubia, A., Fernandez-Salguero, P., & Dorado, P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 23, 616-620 (2001
36. Sibbing, D., et al. Cytochrome 2C1917 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogreltreated patients with coronary stent placement. Circulation 121, 512-518 (2010